Intech Investment Management LLC Buys 10,976 Shares of Guardant Health, Inc. (NASDAQ:GH)

Intech Investment Management LLC increased its holdings in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 33.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 43,824 shares of the company's stock after buying an additional 10,976 shares during the period. Intech Investment Management LLC's holdings in Guardant Health were worth $1,339,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the business. Nikko Asset Management Americas Inc. lifted its stake in Guardant Health by 15.6% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 1,464,213 shares of the company's stock valued at $44,732,000 after buying an additional 197,729 shares in the last quarter. Kimelman & Baird LLC bought a new stake in shares of Guardant Health during the fourth quarter worth $58,000. Cibc World Markets Corp bought a new stake in Guardant Health in the 4th quarter valued at $346,000. Commonwealth Equity Services LLC acquired a new position in Guardant Health in the 4th quarter worth $293,000. Finally, Swiss National Bank increased its holdings in Guardant Health by 1.0% during the 4th quarter. Swiss National Bank now owns 241,900 shares of the company's stock worth $7,390,000 after purchasing an additional 2,500 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Guardant Health Stock Performance

Shares of NASDAQ GH traded down $0.28 during mid-day trading on Tuesday, reaching $46.46. The company had a trading volume of 1,304,391 shares, compared to its average volume of 2,147,558. The firm has a market cap of $5.73 billion, a price-to-earnings ratio of -13.05 and a beta of 1.50. The business's 50-day simple moving average is $44.20 and its 200 day simple moving average is $33.95. Guardant Health, Inc. has a one year low of $15.81 and a one year high of $50.89.

Remove Ads

Guardant Health (NASDAQ:GH - Get Free Report) last issued its earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The business had revenue of $201.81 million for the quarter, compared to analyst estimates of $192.50 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. On average, sell-side analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on GH. Barclays initiated coverage on Guardant Health in a report on Thursday, January 23rd. They set an "overweight" rating and a $60.00 price objective for the company. Piper Sandler raised their price target on shares of Guardant Health from $34.00 to $50.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. JPMorgan Chase & Co. boosted their price objective on shares of Guardant Health from $50.00 to $55.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Guggenheim reaffirmed a "buy" rating and issued a $56.00 target price on shares of Guardant Health in a research report on Monday, February 24th. Finally, The Goldman Sachs Group boosted their price target on shares of Guardant Health from $49.00 to $56.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Twenty investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Guardant Health currently has an average rating of "Buy" and an average price target of $48.40.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.